

November 6th, 2006

PharmaDesign releases PharmaGPEP™ ver.3SP, a peptide library designed based on bioinformatics and sequence/modification/structure information

PharmaDesign Inc. (Tokyo, Japan, CEO: Toshio Furuya) is pleased to announce the release of PharmaGPEP™ ver.3SP.

PharmaGPEP is a series of peptide ligand candidate libraries that target G-protein coupled receptors (GPCRs). PharmaDesign has released PharmaGPEP™ ver.1 in January 2004 followed by PharmaGPEP™ ver.2S, a collection of peptides with one or two disulfide bonds each released in December 2005. Both versions have been received well by pharmaceutical companies working on GPCRs.

PharmaGPEP™ ver.3SP was designed based on two new unique prediction methods in addition to the previous versions'.

1. Based on information of sequences and modification at cleavage sites of active peptides

Because many active peptides have characteristic sequences and amidation at C-termini, pattern-matching method was used to predict C-terminal cleavage sites in precursor proteins.

2. Based on information of sequences and structures at cleavage sites of active peptides

Hidden Markov Model (HMM) was used to predict cleavage sites based on amino acid frequencies, and machine-learning method was used to predict based on structural information including disorder regions* (regions that do not form certain three-dimensional structure).

* This method to predict to disorder regions was developed by a collaboration of PharmaDesign and Computational Biology Research Center (CBRC) of National Institute of Advanced Industrial Science and Technology (AIST).

PharmaDesign hopes to expand our services to help drug discovery with this new product.

■ About PharmaDesign, Inc.

PharmaDesign, Inc. is a genome drug discovery company established in 1999, and its core technologies are structural bioinformatics and rational drug design. We conduct contract researches for clients including pharmaceutical companies as well as our own drug discovery researches by searching drug target molecules and identifying lead compounds. We also

develop and sell small compound libraries called PharmaGCHEM™.
For more information, please visit <http://www.pharmadesign.co.jp/> .

■ Contact

Naoyuki Nemoto

General Manager, Business Promotion Division

Phone: 03-3523-9630

E-mail: sales@pharmadesign.co.jp